Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Biotechnology

Healthcare
$3.57 -3.40%

-$0.24 today

Market cap
$104.19M
Beta
1.73
P/E (TTM)
-40.8
EPS (TTM)
-$0.17
52W Low $3.71High $8.74

Volume 1.39M

Average 0.65M

UNCY Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Unicycive Therapeutics, Inc.NASDAQ: UNCY

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns negative

Q1 FY2026 net income was -$12.82M, compared with $570K a year earlier. Trailing-twelve-month net income was -$39.95M. Over 3 fiscal years it compounded at +13.7% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$17.43M (-34.4%) for the fiscal year ending Dec 2026, a slowdown from the -27.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.82M-12.6% QoQ
Last fiscal yearDec 2025
-$26.56M-27.7% YoY
LTMMar 2026
-$39.95M+162.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2349.6%+106.5%+2456.2 pp
1 year-27.7%-34.4%-6.7 pp
3-year CAGR+13.7%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(26.56M) USD
Year-over-year change
+27.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How UNCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +162.9% is the 2nd highest of 10, against a peer median of -7.7%.
  • Over three fiscal years its annual growth of +13.7% compares with a peer median of +2.0%.
UNCY Competitors
Net Income for UNCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMUXImmunic, Inc.LTM Mar 2026$104.29M USD+8.2%-6.9%—
CBUSCibus, Inc.LTM Mar 2026$103.27M USD-65.4%+96.0%2409.4%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$86.3M USD+66.7%—2193.7%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$78.34M USD+28.7%+2.0%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$77.27M USD-7.7%+35.7%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$58.88M USD-22.2%-28.5%—
BMEABiomea Fusion, Inc.LTM Mar 2026$44.95M USD-65.1%-8.9%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$39.95M USD+162.9%+13.7%—
VXRTVaxart, Inc.LTM Mar 2026$37.1M USD+163.8%—14.5%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$12.18M CAD-73.6%+21.9%66.4%
Peer median (excluding UNCY) —-7.7%+2.0%1130.0%

Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Depreciation & Amortization13K161K284K428K572K
Deferred Income Tax00000
Stock-Based Compensation966K1.05M1.77M2.35M2.64M
Change in Working Capital(105K)1.18M(93K)(427K)(5.95M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.24M1.27M1.28M790K(2.51M)
Other Working Capital(1.35M)(89K)(1.37M)(1.22M)(3.45M)
Other Non-Cash Items3.38M21K10.3M5.8M(2.02M)
Operating Cash Flow(5.77M)(15.65M)(18.28M)(28.58M)(31.32M)
Capital Expenditures(29K)(2K)(12K)(72K)(24K)
Acquisitions (Net)00000
Purchases of Investments0000(12.07M)
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(29K)(2K)(12K)(72K)(12.1M)
Debt Repayment(15K)0000
Common Stock Issued22.27M11K0683K48.08M
Common Stock Repurchased00000
Dividends Paid000(1.1M)0
Other Financing Activities119K(482K)(2.65M)(4.5M)(1.61M)
Financing Cash Flow22.38M(471K)27.54M45.09M46.47M
Effect of Forex Changes00000
Net Change in Cash16.58M(16.12M)9.25M16.44M3.06M
Free Cash Flow(5.8M)(15.65M)(18.3M)(28.65M)(31.34M)

Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Intrinsic Alpha fair value

Locked

Current Price

$3.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.